Keros Therapeutics Inc

KROS

Equity

ISIN null / Valor 53581630

NASDAQ (2025-11-21)

USD 17.39+3.39%

Keros Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Keros Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of novel therapeutics aimed at modulating the transforming growth factor-beta (TGF-β) superfamily of proteins. These regulatory proteins play a crucial role in the growth, repair, and maintenance of blood cells and various tissues. By leveraging its deep expertise in TGF-β science, Keros Therapeutics aims to create innovative treatments that offer potentially disease-modifying benefits for patients with unmet medical needs. The company's focus on TGF-β signaling positions it at the forefront of developing targeted therapies that could significantly impact patient care in areas where current treatment options are limited.

Summarized from source with an LLMView SourceSector: Technology

Net Loss Increases

Keros Therapeutics Inc reported a net loss of $45.3 million for the second quarter of 2024, up from $37.5 million in the second quarter of 2023. The rise in net loss of $7.8 million is primarily attributed to increased research and development activities and additional investments to advance the company's clinical and corporate objectives.

Higher Research and Development Expenses

Research and development expenses surged to $40.5 million in Q2 2024 compared to $32.5 million in Q2 2023. This $8.0 million increase reflects expanded R&D efforts, enhanced manufacturing activities, and higher personnel costs to support the progression of Keros’ therapeutic pipeline.

Increased General and Administrative Costs

General and administrative expenses rose to $10.0 million in the second quarter of 2024 from $8.8 million in the same quarter of 2023. The $1.2 million increase is mainly due to higher personnel expenses and external costs associated with the company’s organizational growth.

Strong Cash Position

As of June 30, 2024, Keros Therapeutics Inc held $405.9 million in cash and cash equivalents, up from $331.1 million at the end of December 2023. This robust cash reserve is expected to fund the company’s operating expenses and capital expenditures through 2027.

Summarized from source with an LLMView Source

Key figures

-67.7%1Y

-62.5%3Y

-75.5%5Y

Performance

143%1Y

93.0%3Y

84.6%5Y

Volatility